Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up

Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up

Abstract Background Following a 30-year development process, RTS,S/AS01 E (GSK, Belgium) is the first malaria vaccine to reach Phase IV assessments. The World Health Organization-commissioned Malaria Vaccine Implementation Programme (MVIP) is coordinating the delivery of RTS,S/AS01 E through routine...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Nicolas Praet, Kwaku Poku Asante, Marie‐Cécile Bozonnat, Elaine Jacqueline Akité, Patrick Ansah, Laurence Baril, Owusu Boahen, Yolanda Guerra Mendoza, Valérie Haine, Simon Kariuki, Mathieu Lamy, Kenneth Maleta, Randy G. Mungwira, Latif Ndeketa, Abraham Oduro, Bernhards Ogutu, Fredrick Olewe, Martina Oneko, Mattéa Orsini, François Roman, Édith Roset Bahmanyar, Dominique Rosillon, Lode Schuerman, Valentine Sing’oei, Dianne J. Terlouw, Stéphanie Wéry, Walter Otieno, Jean‐Yves Pirçon
Format: Artigo
Langue:anglais
Publié: 2022
Accès en ligne:https://doi.org/10.1186/s12936-022-04144-3
https://malariajournal.biomedcentral.com/track/pdf/10.1186/s12936-022-04144-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doi.org/10.1186/s12936-022-04144-3
https://malariajournal.biomedcentral.com/track/pdf/10.1186/s12936-022-04144-3

Documents similaires